OBJECTIVES: The present study reports on the preparation and testing of a desoxycholate amphotericin B (D-AMB) sustained delivery system based on poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) polymeric blends (Nano-D-AMB) aimed at reducing the number of AMB administrations required to treat mycosis. METHODS: BALB/c mice were infected with the yeast Paracoccidioides brasiliensis intravenously to mimic the chronic form of paracoccidioidomycosis. At 30 days post-infection, the animals were treated with Nano-D-AMB [6 mg/kg of encapsulated D-AMB, intraperitoneally (ip), interval of 72 h] or D-AMB (2 mg/kg, ip, interval of 24 h). Drug efficacy was investigated by the fungal burden recovery from tissues. Toxicity was assessed by renal and hepatic biochemical parameters, physical appearance of the animals and haematological investigation. The control groups used were non-infected and the infected mice mock treated with PBS. RESULTS: Nano-D-AMB presented results comparable to free D-AMB, with a marked antifungal efficacy. The Nano-D-AMB-treated group presented lower loss of body weight and absence of stress sign (piloerection and hypotrichosis) observed after D-AMB treatment. No renal [blood urea nitrogen (BUN), creatinine] or hepatic (pyruvic and oxalacetic glutamic transaminases) biochemical abnormalities were found. The micronucleus assay showed no significant differences in both the micronucleus frequency and percentage of polychromatic erythrocytes for Nano-D-AMB, indicating the absence of genotoxicity and cytotoxic effects. CONCLUSIONS: The D-AMB-coated PLGA-DMSA nanoparticle showed antifungal efficacy, fewer undesirable effects and a favourable extended dosing interval. Nano-D-AMB comprises an AMB formulation able to lessen the number of drug administrations. Further studies would elucidate whether Nano-D-AMB would be useful to treat systemic fungal infections such as paracoccidioidomycosis, candidiasis, aspergillosis and cryptococcosis.
OBJECTIVES: The present study reports on the preparation and testing of a desoxycholateamphotericin B (D-AMB) sustained delivery system based on poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) polymeric blends (Nano-D-AMB) aimed at reducing the number of AMB administrations required to treat mycosis. METHODS: BALB/c mice were infected with the yeastParacoccidioides brasiliensis intravenously to mimic the chronic form of paracoccidioidomycosis. At 30 days post-infection, the animals were treated with Nano-D-AMB [6 mg/kg of encapsulated D-AMB, intraperitoneally (ip), interval of 72 h] or D-AMB (2 mg/kg, ip, interval of 24 h). Drug efficacy was investigated by the fungal burden recovery from tissues. Toxicity was assessed by renal and hepatic biochemical parameters, physical appearance of the animals and haematological investigation. The control groups used were non-infected and the infected mice mock treated with PBS. RESULTS:Nano-D-AMB presented results comparable to free D-AMB, with a marked antifungal efficacy. The Nano-D-AMB-treated group presented lower loss of body weight and absence of stress sign (piloerection and hypotrichosis) observed after D-AMB treatment. No renal [blood ureanitrogen (BUN), creatinine] or hepatic (pyruvic and oxalacetic glutamic transaminases) biochemical abnormalities were found. The micronucleus assay showed no significant differences in both the micronucleus frequency and percentage of polychromatic erythrocytes for Nano-D-AMB, indicating the absence of genotoxicity and cytotoxic effects. CONCLUSIONS: The D-AMB-coated PLGA-DMSA nanoparticle showed antifungal efficacy, fewer undesirable effects and a favourable extended dosing interval. Nano-D-AMB comprises an AMB formulation able to lessen the number of drug administrations. Further studies would elucidate whether Nano-D-AMB would be useful to treat systemic fungal infections such as paracoccidioidomycosis, candidiasis, aspergillosis and cryptococcosis.
Authors: Maheshkumar P Soni; Madhuvanti V Mahajan; Rohit V Dhumal; Sharad Bhagat; Dinesh Tiwari; Rajiv V Gaikwad; Abdul Samad; Padma V Devarajan; Geeta R Vanage Journal: Drug Deliv Transl Res Date: 2013-10 Impact factor: 4.617
Authors: André C Amaral; Alexandre F Marques; Julián E Muñoz; Anamélia L Bocca; Andreza R Simioni; Antonio C Tedesco; Paulo C Morais; Luiz R Travassos; Carlos P Taborda; Maria Sueli S Felipe Journal: Br J Pharmacol Date: 2010-02-05 Impact factor: 8.739
Authors: Mahasen A Radwan; Bushra T AlQuadeib; Lidija Šiller; Matthew C Wright; Benjamin Horrocks Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419
Authors: Erika Seki Kioshima; Patrícia de Souza Bonfim de Mendonça; Marcus de Melo Teixeira; Isis Regina Grenier Capoci; André Amaral; Franciele Abigail Vilugron Rodrigues-Vendramini; Bruna Lauton Simões; Ana Karina Rodrigues Abadio; Larissa Fernandes Matos; Maria Sueli Soares Felipe Journal: J Fungi (Basel) Date: 2021-02-02
Authors: Ana Karina R Abadio; Erika S Kioshima; Marcus M Teixeira; Natalia F Martins; Bernard Maigret; Maria Sueli S Felipe Journal: BMC Genomics Date: 2011-01-27 Impact factor: 3.969